APA (7th ed.) Citation

Tichy, E., Torres, A., Bassetti, M., Kongnakorn, T., Di Virgilio, R., Irani, P., & Charbonneau, C. (2020). Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy. Clinical therapeutics, 42(5), 802-817. https://doi.org/10.1016/j.clinthera.2020.03.014

Chicago Style (17th ed.) Citation

Tichy, Eszter, Antoni Torres, Matteo Bassetti, Thitima Kongnakorn, Roberto Di Virgilio, Paurus Irani, and Claudie Charbonneau. "Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy." Clinical Therapeutics 42, no. 5 (2020): 802-817. https://doi.org/10.1016/j.clinthera.2020.03.014.

MLA (9th ed.) Citation

Tichy, Eszter, et al. "Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy." Clinical Therapeutics, vol. 42, no. 5, 2020, pp. 802-817, https://doi.org/10.1016/j.clinthera.2020.03.014.